SCHEMBL469849

SCHEMBL469849

Fc1ccc(NC(=S)NNC(=S)Nc2ccc(F)cc2)cc1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 3/20 0.84
GAA P10253 6/20 0.76
IDO1 P14902 1/20 0.69
MEN1 O00255 4/20 0.67
KMT2A Q03164 4/20 0.67
MAPT P10636 3/20 0.67
LMNA P02545 2/20 0.67
SMN1; SMN2 Q16637 2/20 0.67
MAPK1 P28482 2/20 0.67
POLB P06746 1/20 0.62
MAOB P27338 2/20 0.60
RAB9A P51151 2/20 0.60
NPC1 O15118 1/20 0.60
MAOA P21397 1/20 0.60
PLK4 O00444 1/20 0.58
DAPK3 O43293 1/20 0.58
RPS6KA5 O75582 1/20 0.58
MAP4K4 O95819 1/20 0.58
ERBB2 P04626 1/20 0.58
PRKCG P05129 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10099725 0.90 GAA (0.83) NOX1GAAIDO1MEN1KMT2A
SCHEMBL469851 0.88 NOX1 (0.73) NOX1GAAIDO1MEN1KMT2A
SCHEMBL28641155 0.87 NOX1 (0.66) NOX1GAAIDO1MEN1KMT2A
SCHEMBL19277757 0.87 KMT2A (0.74) NOX1GAAIDO1MEN1KMT2A
SCHEMBL18031169 0.86 GAA (1.00) NOX1GAAIDO1MEN1KMT2A
SCHEMBL28679366 0.84 GAA (0.71) NOX1GAAIDO1MEN1KMT2A
SCHEMBL10710275 0.82 NOX1 (0.85) NOX1GAAIDO1MEN1KMT2A
SCHEMBL6302055 0.82 GAA (0.64) NOX1GAAIDO1MEN1KMT2A
SCHEMBL455548 0.82 IDO1 (1.00) NOX1GAAIDO1MEN1KMT2A
SCHEMBL6302052 0.82 GAA (0.64) NOX1GAAIDO1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012033601-A1 THIOSEMICARBAZONES WITH MDR1 - INVERSE ACTIVITY THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2012-03-15 WO disclosed
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) 2010-12-16 US disclosed
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES (HU) 2010-12-16 US disclosed
WO-2009102433-A2 COMPOUNDS WITH MDR1-INVERSE ACTIVITY THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316655-A1 COMPOUNDS WITH MDR1-INVERSE ACTIVITY ABCC1, ABCB1, ABCC2 NOX1 4166/4885GAA 231/4885IDO1 4305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.